Harvard Bioscience, Inc. logo

Harvard Bioscience, Inc. (HBI0)

Market Closed
17 Jul, 20:00
XMUN XMUN
0. 42
0
0%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
0.21 Eps
0.42
Previous Close
Add Transaction
Day Range
0.42 0.42
Year Range
0.42 6.7
Want to track HBI0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

HBI0 closed yesterday higher at €0.42, an increase of 0% from Thursday's close, completing a monthly increase of 0% or €0. Over the past 12 months, HBI0 stock lost -92.6316%.
HBI0 is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0259%, based on the last three reports.
Harvard Bioscience, Inc. has completed 1 stock splits, with the recent split occurring on Mar 16, 2026.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

HBI0 Chart

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
Harvard Bioscience Q4 Earnings Call Highlights

Harvard Bioscience Q4 Earnings Call Highlights

Harvard Bioscience (NASDAQ: HBIO) executives highlighted a year of "foundation building" and cost and balance sheet actions while outlining expectations for a return to growth in 2026 during the company's fourth-quarter and full-year 2025 earnings call. Management points to refinancing, manufacturing consolidation, and governance changes President and CEO John Duke said 2025 represented a "pivotal year

Defenseworld | 4 months ago
Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript

Seekingalpha | 4 months ago

Harvard Bioscience, Inc. (HBI0) FAQ

What is the stock price today?

The current price is €0.42.

On which exchange is it traded?

Harvard Bioscience, Inc. is listed on XMUN.

What is its stock symbol?

The ticker symbol is HBI0.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Harvard Bioscience, Inc. ever had a stock split?

Harvard Bioscience, Inc. had 1 splits and the recent split was on Mar 16, 2026.

Harvard Bioscience, Inc. Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
John D. Duke CEO
XMUN Exchange
US4169062043 ISIN
US Country
339 Employees
- Last Dividend
16 Mar 2026 Last Split
7 Dec 2000 IPO Date

Overview

Harvard Bioscience, Inc. is a premier developer, manufacturer, and seller of life science applications and technologies, reaching a global audience. With a foundation that dates back to 1901, the company has established itself as a leader in the life science community, catering to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories. Harvard Bioscience also extends its offerings to contract research organizations and academic labs. Its product portfolio spans a wide range of cellular and molecular technology products designed to advance scientific research and drug development. Headquartered in Holliston, Massachusetts, the company is committed to innovation in life science research, emphasizing quality and precision in its products and services.

Products and Services

  • Syringe and Peristaltic Infusion Pump Products
    • Designed for precision liquid handling, these pumps are essential for dosing and infusion applications in laboratory settings.

  • Electroporation and Electrofusion Instruments
    • Used for cell manipulation techniques, these instruments facilitate the introduction of substances into cells or the fusion of cells, playing a critical role in genetic and cellular research.

  • Amino Acid Analyzers, Spectrophotometers, and Molecular Level Testing Equipment
    • Key in analyzing biological specimens, these devices support the detection and quantification of substances, aiding in complex molecular research.

  • Precision Scientific Measuring Instrumentation and Equipment
    • Includes data acquisition systems for cellular analysis, micro electrode array solutions for in vivo and in vitro recordings, underpinning a broad spectrum of physiological and biological research.

  • Preclinical Products
    • Offer a platform to assess vital physiological data from organisms, supporting research, drug discovery, and drug development through telemetry systems, behavior products, and surgical instruments for lab research.

  • Turn-key Respiratory System Solutions
    • Comprehensive respiratory analysis systems, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation tools, crucial for respiratory research.

  • Inhalation and Exposure Systems
    • Provide a controlled environment for the study of respiratory health, pollutants, and therapeutics, facilitating inhalation research and drug efficacy studies.

  • GLP-Capable Data Acquisition and Analysis Systems
    • These systems offer robust data gathering and analysis capabilities adhering to Good Laboratory Practice standards, essential for high-quality research output.

Harvard Bioscience markets its innovative products through a combination of sales organizations, websites, and distributors. The brand portfolio includes recognized names such as Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab, underscoring its commitment to quality and scientific advancement.

Contact Information

Address: 84 October Hill Road
Phone: 508 893 8999